News on research and diagnostic developments in neuroscience.
The partners plan to validate blood-based microRNAs as biomarkers for the early detection of pulmonary and neurodegenerative diseases.
The $12 million PRIME study will involve 2,000 veterans with major depressive disorder and 250 healthcare providers across 21 VA medical centers.
AmCare Genomics said that it has a large network that would enable it to raise awareness about Genomic Vision's test for facioscapulohumeral muscular dystrophy.
The test analyzes clinically relevant genetic variants for 14 genes related to certain pain and mental health medication responses to help guide clinicians' prescribing decisions.
The developers said that their multivariant analysis does a better job than using APOE E4 alone at identifying those at greatest risk of developing Alzheimer's.